GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-11.32%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$212M
AUM Growth
+$212M
(-36%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-65.43%
Top 10 Holdings %
Top 10 Hldgs %
61.58%
Holding
33
New
4
Increased
5
Reduced
13
Closed
7
Top Buys
| 1 |
Xenon Pharmaceuticals
XENE
|
$9.61M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$8.74M |
| 3 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$4.93M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$4.13M |
| 5 |
MREO
Mereo BioPharma
MREO
|
$4.03M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$83.4M |
| 2 |
Neurogene
NGNE
|
$12.8M |
| 3 |
Olema Pharmaceuticals
OLMA
|
$11.9M |
| 4 |
Pliant Therapeutics
PLRX
|
$11.3M |
| 5 |
Arcellx
ACLX
|
$8.35M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $17.7M | 8.32% | 505,007 +250,007 | +98% | +$8.74M |
|
2
Cytokinetics
CYTK
$4.23B
| $16.9M | 7.98% | 360,000 +44,000 | +14% | +$2.07M |
|
|
3
KalVista Pharmaceuticals
KALV
$678M
| $15.1M | 7.13% | 1,787,003 +487,500 | +38% | +$4.13M |
|
4
Viridian Therapeutics
VRDN
$1.5B
| $14.4M | 6.78% | 750,000 | – | – |
|
|
5
Pliant Therapeutics
PLRX
$101M
| $13.9M | 6.55% | 1,055,000 -855,121 | -45% | -$11.3M |
|
|
ABVX
6
Abivax
ABVX
$6.12B
| $12.1M | 5.69% | 1,648,523 -480,250 | -23% | -$3.52M |
|
7
Dynavax Technologies
DVAX
$1.19B
| $11M | 5.18% | 860,000 -466,234 | -35% | -$5.95M |
|
|
8
Neurogene
NGNE
$264M
| $10.1M | 4.77% | 442,761 -561,530 | -56% | -$12.8M |
|
9
Evolus
EOLS
$494M
| $9.89M | 4.66% | 895,524 -274,476 | -23% | -$3.03M |
|
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $9.61M | 4.53% | +245,272 | New | +$9.61M |
|
11
Unicycive Therapeutics
UNCY
$74M
| $8.72M | 4.11% | 10,980,000 +2,421,000 | +28% | +$1.92M |
|
12
Zura Bio
ZURA
$133M
| $7.93M | 3.73% | 3,170,194 -93,478 | -3% | -$234K |
|
|
AUTL
13
Autolus Therapeutics
AUTL
$399M
| $7.07M | 3.33% | 3,009,392 +197,437 | +7% | +$464K |
|
14
Jasper Therapeutics
JSPR
$45.5M
| $6.89M | 3.25% | 322,380 | – | – |
|
15
Merus
MRUS
$4.98B
| $6.65M | 3.13% | 158,092 -91,908 | -37% | -$3.86M |
|
16
Dianthus Therapeutics
DNTH
$759M
| $6M | 2.83% | 275,000 | – | – |
|
|
BBOT
17
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $5.25M | 2.47% | 500,000 | – | – |
|
|
UPB
18
Upstream Bio, Inc. Common Stock
UPB
$923M
| $4.93M | 2.32% | +300,000 | New | +$4.93M |
|
19
Context Therapeutics
CNTX
$75.4M
| $4.92M | 2.32% | 4,683,711 -2,251,271 | -32% | -$2.36M |
|
20
Voyager Therapeutics
VYGR
$186M
| $4.69M | 2.21% | 826,751 -133,202 | -14% | -$755K |
|
|
ORKA
21
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $4.44M | 2.09% | 228,803 -285,856 | -56% | -$5.54M |
|
|
MREO
22
Mereo BioPharma
MREO
$272M
| $4.03M | 1.9% | +1,150,000 | New | +$4.03M |
|
23
Rezolute
RZLT
$619M
| $3.05M | 1.44% | +621,894 | New | +$3.05M |
|
24
ProMIS Neurosciences
PMN
$28M
| $2.51M | 1.18% | 2,645,128 -145,570 | -5% | -$138K |
|
|
OPTN
25
DELISTED
OptiNose
OPTN
| $2.47M | 1.17% | 370,269 -12,490,867 | -97% | -$83.4M |
|